IC-MPGN
10 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (NCT05067127) | Apellis Pharmaceuticals, Inc. | 2021-11-12 |
| Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN (NCT04572854) | Apellis Pharmaceuticals, Inc. | 2021-09-07 |
| Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study (NCT03723512) | Mario Negri Institute for Pharmacological Research | 2018-12-06 |
| A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471 (NCT03459443) | Alexion Pharmaceuticals, Inc. | 2018-06-20 |
| C3G/Primary IC-MPGN EAP (NCT04729062) | Apellis Pharmaceuticals, Inc. |
Track IC-MPGN automatically
Every clearance here is in the API, with alerts when new ones post.